Stock SOBI SWEDISH ORPHAN BIOVITRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:42 2024-06-05 am EDT 		5-day change 1st Jan Change
288.6 SEK +1.48% Intraday chart for Swedish Orphan Biovitrum AB +3.89% +8.09%
May. 28 BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB CI
May. 24 Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment DJ

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 45,437 48,345 54,631 63,845 90,680 98,086 - -
Enterprise Value (EV) 1 61,161 62,093 64,131 71,251 109,945 112,544 106,955 98,914
P/E ratio 13.8 x 15.2 x 20.5 x 24.4 x 36.1 x 28.9 x 19.8 x 14.7 x
Yield - - - - - - - -
Capitalization / Revenue 3.19 x 3.17 x 3.52 x 3.4 x 4.1 x 3.99 x 3.6 x 3.2 x
EV / Revenue 4.29 x 4.07 x 4.13 x 3.79 x 4.97 x 4.58 x 3.93 x 3.22 x
EV / EBITDA 9.99 x 9.09 x 11.2 x 10.5 x 14.3 x 12.6 x 10.1 x 7.87 x
EV / FCF -3.39 x 49.7 x 12.6 x 15.5 x 27.1 x 18.8 x 14.8 x 11.4 x
FCF Yield -29.5% 2.01% 7.96% 6.45% 3.7% 5.32% 6.74% 8.78%
Price to Book 2.74 x 2.42 x 2.46 x 2.52 x 2.79 x 2.69 x 2.41 x 2.13 x
Nbr of stocks (in thousands) 294,091 291,059 295,145 295,991 339,627 339,868 - -
Reference price 2 154.5 166.1 185.1 215.7 267.0 288.6 288.6 288.6
Announcement Date 2/13/20 2/18/21 2/10/22 2/8/23 2/8/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 14,248 15,261 15,529 18,790 22,123 24,571 27,246 30,683
EBITDA 1 6,121 6,830 5,740 6,758 7,676 8,917 10,598 12,561
EBIT 1 4,533 4,818 3,733 4,488 4,485 5,341 6,966 8,966
Operating Margin 31.81% 31.57% 24.04% 23.89% 20.27% 21.74% 25.57% 29.22%
Earnings before Tax (EBT) 1 4,247 4,217 3,295 3,321 2,954 4,267 6,216 8,358
Net income 1 3,304 3,245 2,679 2,638 2,409 3,412 4,986 6,703
Net margin 23.19% 21.26% 17.25% 14.04% 10.89% 13.89% 18.3% 21.85%
EPS 2 11.22 10.90 9.030 8.840 7.390 9.994 14.55 19.57
Free Cash Flow 1 -18,051 1,250 5,103 4,593 4,063 5,988 7,207 8,688
FCF margin -126.69% 8.19% 32.86% 24.44% 18.37% 24.37% 26.45% 28.32%
FCF Conversion (EBITDA) - 18.3% 88.9% 67.96% 52.93% 67.15% 68% 69.17%
FCF Conversion (Net income) - 38.52% 190.48% 174.11% 168.66% 175.47% 144.54% 129.61%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/18/21 2/10/22 2/8/23 2/8/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,896 4,925 3,876 3,999 5,991 5,239 4,872 5,168 6,844 6,256 5,126 5,955 7,433 6,570 6,146
EBITDA 1 2,061 1,461 997 1,278 2,493 2,159 1,286 1,585 2,645 2,377 1,398 2,040 3,075 2,713 2,476
EBIT 1 1,525 1,437 423 699 1,916 1,495 413 547 1,691 1,468 549.1 1,296 2,391 1,774 1,537
Operating Margin 31.15% 29.18% 10.91% 17.48% 31.98% 28.54% 8.48% 10.58% 24.71% 23.47% 10.71% 21.77% 32.16% 27% 25.01%
Earnings before Tax (EBT) 1 1,423 674 317 564 1,766 1,325 275 116 1,237 982 226.9 850.6 2,223 1,589 1,384
Net income 1 1,241 543 258 451 1,386 1,067 222 94 1,026 800 179.3 673.3 1,756 1,256 1,093
Net margin 25.35% 11.03% 6.66% 11.28% 23.13% 20.37% 4.56% 1.82% 14.99% 12.79% 3.5% 11.31% 23.62% 19.12% 17.78%
EPS 2 4.180 1.830 0.8600 1.510 4.640 3.560 0.7400 0.3000 2.990 2.330 0.5250 1.965 5.437 3.550 3.090
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/10/22 4/28/22 7/19/22 10/27/22 2/8/23 4/27/23 7/18/23 10/30/23 2/8/24 4/25/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,724 13,748 9,500 7,406 19,265 14,458 8,869 828
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.569 x 2.013 x 1.655 x 1.096 x 2.51 x 1.621 x 0.8369 x 0.0659 x
Free Cash Flow 1 -18,051 1,250 5,103 4,593 4,063 5,988 7,207 8,688
ROE (net income / shareholders' equity) 25.4% 17.5% 12.3% 10.6% 7.98% 10% 12.9% 15.3%
ROA (Net income/ Total Assets) 10.5% 6.91% 5.53% 5.22% 3.81% 4.56% 6.34% 7.21%
Assets 1 31,422 46,970 48,472 50,579 63,228 74,767 78,669 92,993
Book Value Per Share 2 56.40 68.50 75.10 85.60 95.60 107.0 120.0 136.0
Cash Flow per Share 2 12.30 17.50 18.40 15.80 13.70 19.90 22.70 29.20
Capex 1 37 41 47 72 407 576 537 634
Capex / Sales 0.26% 0.27% 0.3% 0.38% 1.84% 2.35% 1.97% 2.07%
Announcement Date 2/13/20 2/18/21 2/10/22 2/8/23 2/8/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Swedish Orphan Biovitrum AB

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
288.6 SEK
Average target price
320 SEK
Spread / Average Target
+10.88%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+8.09% 9.41B
CSL LIMITED Stock CSL Limited
+0.99% 91.72B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
0.00% 39.44B
BIOGEN INC. Stock Biogen Inc.
-10.35% 34.47B
UCB Stock UCB
+64.64% 26.7B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.15% 15.13B
INCYTE CORPORATION Stock Incyte Corporation
-6.98% 13.27B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.77% 11.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-49.19% 10.54B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+141.62% 9.22B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. Financials Swedish Orphan Biovitrum AB